Clinical Pharmacology and Therapeutics
A Textbook of Clinical Pharmacology and ... - clinicalevidence
A Textbook of Clinical Pharmacology and ... - clinicalevidence
- No tags were found...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
EXAMPLES OF ALLERGIC AND OTHER ADVERSE DRUG REACTIONS 69<br />
predisposes to non-immune haemolysis (e.g. primaquine).<br />
Immune mechanisms include the following:<br />
1. Combination of the drug with the red-cell membrane,<br />
with the conjugate acting as an antigen. This has been<br />
shown to occur with penicillin-induced haemolysis, <strong>and</strong><br />
may also occur with chlorpromazine <strong>and</strong> sulphonamides.<br />
2. Alteration of the red-cell membrane by the drug so that it<br />
becomes autoimmunogenic. This may happen with<br />
methyldopa, <strong>and</strong> a direct positive Coombs’ test develops<br />
in about 20% of patients who have been treated with this<br />
drug for more than one year. Frank haemolysis occurs in<br />
only a small proportion of cases. Similar changes can take<br />
place with levodopa, mefenamic acid <strong>and</strong> beta-lactam<br />
antibiotics.<br />
3. Non-specific binding of plasma protein to red cells, <strong>and</strong><br />
thus causing haemolysis. This is believed to occur with<br />
cephalosporins.<br />
Aplastic anaemia as an isolated entity is not common, but<br />
may occur either in isolation or as part of a general depression<br />
of bone marrow activity (pancytopenia). Examples include<br />
chloramphenicol <strong>and</strong> (commonly <strong>and</strong> predictably) cytotoxic<br />
drugs.<br />
Agranulocytosis can be caused by many drugs. Several<br />
different mechanisms are implicated, <strong>and</strong> it is not known<br />
whether allergy plays a part. The drugs most frequently implicated<br />
include the following:<br />
• most cytotoxic drugs (Chapter 48);<br />
• antithyroid drugs (methimazole, carbimazole,<br />
propylthiouracil; Chapter 38);<br />
• sulphonamides <strong>and</strong> sulphonylureas (e.g. tolbutamide,<br />
glipizide; Chapter 37);<br />
• antidepressants (especially mianserin; Chapter 20) <strong>and</strong><br />
antipsychotics (e.g. phenothiazines, clozapine; Chapter 20);<br />
• anti-epileptic drugs (e.g. carbamazepine, felbamate;<br />
Chapter 22).<br />
SYSTEMIC LUPUS ERYTHEMATOSUS<br />
Several drugs (including procainamide, isoniazid, hydralazine,<br />
chlorpromazine <strong>and</strong> anticonvulsants) produce a syndrome<br />
that resembles systemic lupus together with a positive antinuclear<br />
factor test. The development of this is closely related<br />
to dose, <strong>and</strong> in the case of hydralazine it also depends on the<br />
rate of acetylation, which is genetically controlled (Chapter<br />
14). There is some evidence that the drugs act as haptens, combining<br />
with DNA <strong>and</strong> forming antigens. Symptoms usually<br />
disappear when the drug is stopped, but recovery may<br />
be slow.<br />
VASCULITIS<br />
Both acute <strong>and</strong> chronic vasculitis can result from taking<br />
drugs, <strong>and</strong> may have an allergic basis. Acute vasculitis with<br />
purpura <strong>and</strong> renal involvement occurs with penicillins,<br />
sulphonamides <strong>and</strong> penicillamine. A more chronic form can<br />
occur with phenytoin.<br />
RENAL DYSFUNCTION<br />
All clinical manifestations of renal disease can be caused by<br />
drugs, <strong>and</strong> common culprits are non-steroidal anti-inflammatory<br />
drugs <strong>and</strong> angiotensin-converting enzyme inhibitors (which<br />
cause functional <strong>and</strong> usually reversible renal failure in susceptible<br />
patients; Chapters 26 <strong>and</strong> 28). Nephrotic syndrome<br />
results from several drugs (e.g. penicillamine, high-dose captopril,<br />
gold salts) which cause various immune-mediated<br />
glomerular injuries. Interstitial nephritis can be caused by several<br />
drugs, including non-steroidal anti-inflammatory drugs<br />
<strong>and</strong> penicillins, especially meticillin. Cisplatin, aminoglycosides,<br />
amphotericin, radiocontrast media <strong>and</strong> vancomycin<br />
cause direct tubular toxicity. Many drugs cause electrolyte or<br />
acid-base disturbances via their predictable direct or indirect<br />
effects on renal electrolyte excretion (e.g. hypokalaemia <strong>and</strong><br />
hypomagnesaemia from loop diuretics, hyperkalaemia from<br />
potassium-sparing diuretics, converting enzyme inhibitors<br />
<strong>and</strong> angiotensin II receptor antagonists, proximal renal<br />
tubular acidosis from carbonic anhydrase inhibitors), <strong>and</strong><br />
some cause unpredictable toxic effects on acid-base balance<br />
(e.g. distal renal tubular acidosis from amphotericin).<br />
Obstructive uropathy can be caused by uric acid crystals consequent<br />
upon initiation of chemotherapy in patients with<br />
haematological malignancy, <strong>and</strong> – rarely – poorly soluble<br />
drugs, such as sulphonamides, methotrexate or indinavir, can<br />
cause crystalluria.<br />
OTHER REACTIONS<br />
Fever is a common manifestation of drug allergy, <strong>and</strong><br />
should be remembered in patients with fever of unknown<br />
cause.<br />
Liver damage (hepatitis with or without obstructive features)<br />
as a side effect of drugs is important. It may be insidious,<br />
leading slowly to end-stage cirrhosis (e.g. during chronic<br />
treatment with methotrexate) or acute <strong>and</strong> fulminant (as in<br />
some cases of isoniazid, halothane or phenytoin hepatitis).<br />
Chlorpromazine or erythromycin may cause liver involvement<br />
characterized by raised alkaline phosphatase <strong>and</strong> bilirubin<br />
(‘obstructive’ pattern). Gallstones (<strong>and</strong> mechanical<br />
obstruction) can be caused by fibrates <strong>and</strong> other lipid-lowering<br />
drugs (Chapter 27), <strong>and</strong> by octreotide, a somatostatin analogue<br />
used to treat a variety of enteropancreatic tumours,<br />
including carcinoid syndrome <strong>and</strong> VIPomas (vasoactive intestinal<br />
polypeptide) (see Chapter 42). Immune mechanisms are<br />
implicated in some forms of hepatic injury by drugs, but are<br />
seldom solely responsible.